Natco Pharma's Canadian subsidiary has acquired 40 million shares in eGenesis Inc. for USD 8 million. eGenesis is a biotechnology company developing human-compatible organs for transplant through xenotransplantation. This investment aims to support eGenesis' pioneering work in kidney, liver, and heart transplants, potentially addressing the global transplant shortage. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
